PTEN and neoplasm: mMCPcounter predicted an increase in CD3 + T cells, CD8 + T cells, monocytes, lymphatic vessels, and eosinophils, as well as a decrease in mast cells, NK cells, and endothelial cells (p < 0.05) (Figs. 3A, S5A), suggesting enhanced anti-tumor immunity in the Braf/Pten/Cxcr2−/− TME.